{"analyses":[{"ciLowerLimit":"0.76","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.30","groupDescription":"Emotional Functioning, Cycle 3 Day 1","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.9770","paramType":"Odds Ratio (OR)","paramValue":"1.00","statisticalMethod":"Cochran-Mantel-Haenszel"},{"ciLowerLimit":"0.80","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.37","groupDescription":"Emotional Functioning, Cycle 5 Day 1","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.7317","paramType":"Odds Ratio (OR)","paramValue":"1.05","statisticalMethod":"Cochran-Mantel-Haenszel"},{"ciLowerLimit":"0.80","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.39","groupDescription":"Emotional Functioning, Cycle 8 Day 1","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.6937","paramType":"Odds Ratio (OR)","paramValue":"1.06","statisticalMethod":"Cochran-Mantel-Haenszel"},{"ciLowerLimit":"0.66","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.18","groupDescription":"Emotional Functioning, Cycle 12 Day 1","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.3916","paramType":"Odds Ratio (OR)","paramValue":"0.88","statisticalMethod":"Cochran-Mantel-Haenszel"},{"ciLowerLimit":"0.63","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.17","groupDescription":"Emotional Functioning, Cycle 16 Day 1","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.3363","paramType":"Odds Ratio (OR)","paramValue":"0.86","statisticalMethod":"Cochran-Mantel-Haenszel"},{"ciLowerLimit":"0.75","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.55","groupDescription":"Emotional Functioning, Cycle 20 Day 1","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.6761","paramType":"Odds Ratio (OR)","paramValue":"1.08","statisticalMethod":"Cochran-Mantel-Haenszel"},{"ciLowerLimit":"0.71","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.26","groupDescription":"Emotional Functioning, Completion of Treatment/ Early Termination Visit","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.6997","paramType":"Odds Ratio (OR)","paramValue":"0.94","statisticalMethod":"Cochran-Mantel-Haenszel"},{"ciLowerLimit":"0.82","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.72","groupDescription":"Emotional Functioning, Post-Treatment Follow Up 3 Months","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.3592","paramType":"Odds Ratio (OR)","paramValue":"1.19","statisticalMethod":"Cochran-Mantel-Haenszel"},{"ciLowerLimit":"0.62","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.51","groupDescription":"Emotional Functioning, Post-Treatment Follow Up 6 Months","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.8798","paramType":"Odds Ratio (OR)","paramValue":"0.97","statisticalMethod":"Cochran-Mantel-Haenszel"},{"ciLowerLimit":"0.43","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.39","groupDescription":"Emotional Functioning, Post-Treatment Follow Up 9 Months","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.3857","paramType":"Odds Ratio (OR)","paramValue":"0.77","statisticalMethod":"Cochran-Mantel-Haenszel"},{"ciLowerLimit":"0.39","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.85","groupDescription":"Emotional Functioning, Post-Treatment Follow Up 12 Months","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.6854","paramType":"Odds Ratio (OR)","paramValue":"0.85","statisticalMethod":"Cochran-Mantel-Haenszel"},{"ciLowerLimit":"0.11","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"2.70","groupDescription":"Emotional Functioning, Post-Treatment Follow Up 18 Months","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.4533","paramType":"Odds Ratio (OR)","paramValue":"0.54","statisticalMethod":"Cochran-Mantel-Haenszel"},{"ciLowerLimit":"-100.00","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"75.44","groupDescription":"Emotional Functioning, Post-Treatment Follow Up 24 Months","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.3173","paramType":"Difference in Proportion of Responders","paramValue":"-33.33","statisticalMethod":"Cochran-Mantel-Haenszel"},{"ciLowerLimit":"0.87","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.47","groupDescription":"Physical functioning, Cycle 3 Day 1","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.3658","paramType":"Odds Ratio (OR)","paramValue":"1.13","statisticalMethod":"Cochran-Mantel-Haenszel"},{"ciLowerLimit":"0.80","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.36","groupDescription":"Physical functioning, Cycle 5 Day 1","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.7619","paramType":"Odds Ratio (OR)","paramValue":"1.04","statisticalMethod":"Cochran-Mantel-Haenszel"},{"ciLowerLimit":"0.81","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.40","groupDescription":"Physical functioning, Cycle 8 Day 1","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.6580","paramType":"Odds Ratio (OR)","paramValue":"1.06","statisticalMethod":"Cochran-Mantel-Haenszel"},{"ciLowerLimit":"0.88","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.57","groupDescription":"Physical functioning, Cycle 12 Day 1","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.2726","paramType":"Odds Ratio (OR)","paramValue":"1.18","statisticalMethod":"Cochran-Mantel-Haenszel"},{"ciLowerLimit":"0.69","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.29","groupDescription":"Physical functioning, Cycle 16 Day 1","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.6973","paramType":"Odds Ratio (OR)","paramValue":"0.94","statisticalMethod":"Cochran-Mantel-Haenszel"},{"ciLowerLimit":"0.80","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.64","groupDescription":"Physical functioning, Cycle 20 Day 1","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.4470","paramType":"Odds Ratio (OR)","paramValue":"1.15","statisticalMethod":"Cochran-Mantel-Haenszel"},{"ciLowerLimit":"0.68","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.21","groupDescription":"Physical functioning, Completion of Treatment/ Early Termination Visit","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.5150","paramType":"Odds Ratio (OR)","paramValue":"0.91","statisticalMethod":"Cochran-Mantel-Haenszel"},{"ciLowerLimit":"0.88","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.82","groupDescription":"Physical functioning, Post-Treatment Follow Up 3 Months","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.2103","paramType":"Odds Ratio (OR)","paramValue":"1.26","statisticalMethod":"Cochran-Mantel-Haenszel"},{"ciLowerLimit":"0.68","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.66","groupDescription":"Physical functioning, Post-Treatment Follow Up 6 Months","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.7969","paramType":"Odds Ratio (OR)","paramValue":"1.06","statisticalMethod":"Cochran-Mantel-Haenszel"},{"ciLowerLimit":"0.60","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.91","groupDescription":"Physical functioning, Post-Treatment Follow Up 9 Months","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.8300","paramType":"Odds Ratio (OR)","paramValue":"1.07","statisticalMethod":"Cochran-Mantel-Haenszel"},{"ciLowerLimit":"0.53","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"2.55","groupDescription":"Physical functioning, Post-Treatment Follow Up 12 Months","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.6987","paramType":"Odds Ratio (OR)","paramValue":"1.17","statisticalMethod":"Cochran-Mantel-Haenszel"},{"ciLowerLimit":"0.62","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"17.77","groupDescription":"Physical functioning, Post-Treatment Follow Up 18 Months","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.1441","paramType":"Odds Ratio (OR)","paramValue":"3.32","statisticalMethod":"Cochran-Mantel-Haenszel"},{"ciLowerLimit":"-100.00","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"4.39","groupDescription":"Physical functioning, Post-Treatment Follow Up 24 Months","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.3173","paramType":"Difference in proportion of Responders","paramValue":"-66.67","statisticalMethod":"Cochran-Mantel-Haenszel"},{"ciLowerLimit":"0.74","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.25","groupDescription":"Global health status/ QoL, Cycle 3 Day 1","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.7591","paramType":"Odds Ratio (OR)","paramValue":"0.96","statisticalMethod":"Cochran-Mantel-Haenszel"},{"ciLowerLimit":"0.83","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.42","groupDescription":"Global health status/ QoL, Cycle 5 Day 1","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.5403","paramType":"Odds Ratio (OR)","paramValue":"1.09","statisticalMethod":"Cochran-Mantel-Haenszel"},{"ciLowerLimit":"0.89","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.55","groupDescription":"Global health status/ QoL, Cycle 8 Day 1","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.2654","paramType":"Odds Ratio (OR)","paramValue":"1.17","statisticalMethod":"Cochran-Mantel-Haenszel"},{"ciLowerLimit":"0.82","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.48","groupDescription":"Global health status/ QoL, Cycle 12 Day 1","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.5138","paramType":"Odds Ratio (OR)","paramValue":"1.10","statisticalMethod":"Cochran-Mantel-Haenszel"},{"ciLowerLimit":"0.89","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.67","groupDescription":"Global health status/ QoL, Cycle 16 Day 1","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.2138","paramType":"Odds Ratio (OR)","paramValue":"1.22","statisticalMethod":"Cochran-Mantel-Haenszel"},{"ciLowerLimit":"0.88","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.82","groupDescription":"Global health status/ QoL, Cycle 20 Day 1","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.2114","paramType":"Odds Ratio (OR)","paramValue":"1.26","statisticalMethod":"Cochran-Mantel-Haenszel"},{"ciLowerLimit":"0.85","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.53","groupDescription":"Global health status/ QoL, Completion of Treatment/ Early Termination Visit","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.3938","paramType":"Odds Ratio (OR)","paramValue":"1.14","statisticalMethod":"Cochran-Mantel-Haenszel"},{"ciLowerLimit":"0.65","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.38","groupDescription":"Global health status/ QoL, Post-Treatment Follow Up 3 Months","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.7793","paramType":"Odds Ratio (OR)","paramValue":"0.95","statisticalMethod":"Cochran-Mantel-Haenszel"},{"ciLowerLimit":"0.69","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.39","groupDescription":"Global health status/ QoL, Post-Treatment Follow Up 6 Months","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.7370","paramType":"Odds Ratio (OR)","paramValue":"1.08","statisticalMethod":"Cochran-Mantel-Haenszel"},{"ciLowerLimit":"0.55","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.79","groupDescription":"Global health status/ QoL, Post-Treatment Follow Up 9 Months","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.9658","paramType":"Odds Ratio (OR)","paramValue":"0.99","statisticalMethod":"Cochran-Mantel-Haenszel"},{"ciLowerLimit":"0.29","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.46","groupDescription":"Global health status/ QoL, Post-Treatment Follow Up 12 Months","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.3015","paramType":"Odds Ratio (OR)","paramValue":"0.66","statisticalMethod":"Cochran-Mantel-Haenszel"},{"ciLowerLimit":"0.15","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"3.94","groupDescription":"Global health status/ QoL, Post-Treatment Follow Up 18 Months","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.7534","paramType":"Odds Ratio (OR)","paramValue":"0.77","statisticalMethod":"Cochran-Mantel-Haenszel"},{"ciLowerLimit":"-46.49","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"79.82","groupDescription":"Global health status/ QoL, Post-Treatment Follow Up 24 Months","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.5637","paramType":"Difference in Proportion of Responders","paramValue":"16.67","statisticalMethod":"Cochran-Mantel-Haenszel"},{"ciLowerLimit":"0.61","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.06","groupDescription":"Role functioning, Cycle 3 Day 1","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.1177","paramType":"Odds Ratio (OR)","paramValue":"0.80","statisticalMethod":"Cochran-Mantel-Haenszel"},{"ciLowerLimit":"0.88","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.56","groupDescription":"Role functioning, Cycle 5 Day 1","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.2730","paramType":"Odds Ratio (OR)","paramValue":"1.17","statisticalMethod":"Cochran-Mantel-Haenszel"},{"ciLowerLimit":"0.73","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.33","groupDescription":"Role functioning, Cycle 8 Day 1","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.9306","paramType":"Odds Ratio (OR)","paramValue":"0.99","statisticalMethod":"Cochran-Mantel-Haenszel"},{"ciLowerLimit":"0.72","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.32","groupDescription":"Role functioning, Cycle 12 Day 1","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.8631","paramType":"Odds Ratio (OR)","paramValue":"0.97","statisticalMethod":"Cochran-Mantel-Haenszel"},{"ciLowerLimit":"0.95","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.86","groupDescription":"Role functioning, Cycle 16 Day 1","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.0977","paramType":"Odds Ratio (OR)","paramValue":"1.33","statisticalMethod":"Cochran-Mantel-Haenszel"},{"ciLowerLimit":"0.97","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"2.10","groupDescription":"Role functioning, Cycle 20 Day 1","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.0726","paramType":"Odds Ratio (OR)","paramValue":"1.43","statisticalMethod":"Cochran-Mantel-Haenszel"},{"ciLowerLimit":"0.73","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.38","groupDescription":"Role functioning, Completion of Treatment/ Early Termination Visit","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.9974","paramType":"Odds Ratio (OR)","paramValue":"1.00","statisticalMethod":"Cochran-Mantel-Haenszel"},{"ciLowerLimit":"0.72","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.63","groupDescription":"Role functioning, Post-Treatment Follow Up 3 Months","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.7069","paramType":"Odds Ratio (OR)","paramValue":"1.08","statisticalMethod":"Cochran-Mantel-Haenszel"},{"ciLowerLimit":"0.78","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"2.16","groupDescription":"Role functioning, Post-Treatment Follow Up 6 Months","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.3068","paramType":"Odds Ratio (OR)","paramValue":"1.30","statisticalMethod":"Cochran-Mantel-Haenszel"},{"ciLowerLimit":"0.85","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"3.16","groupDescription":"Role functioning, Post-Treatment Follow Up 9 Months","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.1375","paramType":"Odds Ratio (OR)","paramValue":"1.64","statisticalMethod":"Cochran-Mantel-Haenszel"},{"ciLowerLimit":"0.46","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"2.29","groupDescription":"Role functioning, Post-Treatment Follow Up 12 Months","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.9540","paramType":"Odds Ratio (OR)","paramValue":"1.02","statisticalMethod":"Cochran-Mantel-Haenszel"},{"ciLowerLimit":"0.10","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"2.64","groupDescription":"Role functioning, Post-Treatment Follow Up 18 Months","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.4283","paramType":"Odds Ratio (OR)","paramValue":"0.53","statisticalMethod":"Cochran-Mantel-Haenszel"},{"ciLowerLimit":"-95.56","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"100.00","groupDescription":"Role functioning, Post-Treatment Follow Up 24 Months","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","paramType":"Difference in Proportion of Responders","paramValue":"16.67"},{"ciLowerLimit":"0.64","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.10","groupDescription":"Social Functioning, Cycle 3 Day 1","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.2153","paramType":"Odds Ratio (OR)","paramValue":"0.84","statisticalMethod":"Cochran-Mantel-Haenszel"},{"ciLowerLimit":"0.73","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.27","groupDescription":"Social Functioning, Cycle 5 Day 1","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.7878","paramType":"Odds Ratio (OR)","paramValue":"0.96","statisticalMethod":"Cochran-Mantel-Haenszel"},{"ciLowerLimit":"0.61","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.08","groupDescription":"Social Functioning, Cycle 8 Day 1","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.1544","paramType":"Odds Ratio (OR)","paramValue":"0.81","statisticalMethod":"Cochran-Mantel-Haenszel"},{"ciLowerLimit":"0.77","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.40","groupDescription":"Social Functioning, Cycle 12 Day 1","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.8017","paramType":"Odds Ratio (OR)","paramValue":"1.04","statisticalMethod":"Cochran-Mantel-Haenszel"},{"ciLowerLimit":"0.63","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.21","groupDescription":"Social Functioning, Cycle 16 Day 1","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.4295","paramType":"Odds Ratio (OR)","paramValue":"0.88","statisticalMethod":"Cochran-Mantel-Haenszel"},{"ciLowerLimit":"0.68","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.44","groupDescription":"Social Functioning, Cycle 20 Day 1","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.9540","paramType":"Odds Ratio, log","paramValue":"0.99","statisticalMethod":"Cochran-Mantel-Haenszel"},{"ciLowerLimit":"0.69","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.30","groupDescription":"Social Functioning, Completion of Treatment/ Early Termination Visit","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.7494","paramType":"Odds Ratio (OR)","paramValue":"0.95","statisticalMethod":"Cochran-Mantel-Haenszel"},{"ciLowerLimit":"0.74","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.62","groupDescription":"Social Functioning, Post-Treatment Follow Up 3 Months","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.6412","paramType":"Odds Ratio (OR)","paramValue":"1.10","statisticalMethod":"Cochran-Mantel-Haenszel"},{"ciLowerLimit":"0.65","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.67","groupDescription":"Social Functioning, Post-Treatment Follow Up 6 Months","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.8652","paramType":"Odds Ratio (OR)","paramValue":"1.04","statisticalMethod":"Cochran-Mantel-Haenszel"},{"ciLowerLimit":"0.60","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"2.18","groupDescription":"Social Functioning, Post-Treatment Follow Up 9 Months","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.6912","paramType":"Odds Ratio (OR)","paramValue":"1.14","statisticalMethod":"Cochran-Mantel-Haenszel"},{"ciLowerLimit":"0.33","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.86","groupDescription":"Social Functioning, Post-Treatment Follow Up 12 Months","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.5834","paramType":"Odds Ratio (OR)","paramValue":"0.79","statisticalMethod":"Cochran-Mantel-Haenszel"},{"ciLowerLimit":"0.05","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"16.05","groupDescription":"Social Functioning, Post-Treatment Follow Up 18 Months","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.9578","paramType":"Odds Ratio (OR)","paramValue":"0.93","statisticalMethod":"Cochran-Mantel-Haenszel"},{"ciLowerLimit":"-46.49","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"79.82","groupDescription":"Social Functioning, Post-Treatment Follow Up 24 Months","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.5637","paramType":"Difference in Proportion of Responders","paramValue":"16.67","statisticalMethod":"Cochran-Mantel-Haenszel"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"53.1"},{"groupId":"OG001","value":"56.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"456"},{"groupId":"OG001","value":"444"}],"units":"Participants"}],"title":"Physical Functioning, Cycle 3 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"49.0"},{"groupId":"OG001","value":"50.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"439"},{"groupId":"OG001","value":"423"}],"units":"Participants"}],"title":"Physical Functioning, Cycle 5 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"47.8"},{"groupId":"OG001","value":"49.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"414"},{"groupId":"OG001","value":"403"}],"units":"Participants"}],"title":"Physical Functioning, Cycle 8 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"47.1"},{"groupId":"OG001","value":"51.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"378"},{"groupId":"OG001","value":"358"}],"units":"Participants"}],"title":"Physical Functioning, Cycle 12 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"50.5"},{"groupId":"OG001","value":"48.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"333"},{"groupId":"OG001","value":"312"}],"units":"Participants"}],"title":"Physical Functioning, Cycle 16 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"46.6"},{"groupId":"OG001","value":"50.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"253"},{"groupId":"OG001","value":"234"}],"units":"Participants"}],"title":"Physical Functioning, Cycle 20 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"46.8"},{"groupId":"OG001","value":"44.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"370"},{"groupId":"OG001","value":"366"}],"units":"Participants"}],"title":"Physical Functioning, Completion of Treatment/ Early Termination Visit"},{"categories":[{"measurements":[{"groupId":"OG000","value":"41.3"},{"groupId":"OG001","value":"47.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"235"},{"groupId":"OG001","value":"236"}],"units":"Participants"}],"title":"Physical Functioning, Post-Treatment Follow Up 3 Months"},{"categories":[{"measurements":[{"groupId":"OG000","value":"42.2"},{"groupId":"OG001","value":"43.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"147"},{"groupId":"OG001","value":"164"}],"units":"Participants"}],"title":"Physical Functioning, Post-Treatment Follow Up 6 Months"},{"categories":[{"measurements":[{"groupId":"OG000","value":"46.4"},{"groupId":"OG001","value":"46.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"84"},{"groupId":"OG001","value":"98"}],"units":"Participants"}],"title":"Physical Functioning, Post-Treatment Follow Up 9 Months"},{"categories":[{"measurements":[{"groupId":"OG000","value":"44.4"},{"groupId":"OG001","value":"50.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"45"},{"groupId":"OG001","value":"58"}],"units":"Participants"}],"title":"Physical Functioning, Post-Treatment Follow Up 12 Months"},{"categories":[{"measurements":[{"groupId":"OG000","value":"35.7"},{"groupId":"OG001","value":"56.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"16"}],"units":"Participants"}],"title":"Physical Functioning, Post-Treatment Follow Up 18 Months"},{"categories":[{"measurements":[{"groupId":"OG000","value":"100"},{"groupId":"OG001","value":"33.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"6"}],"units":"Participants"}],"title":"Physical Functioning, Post-Treatment Follow Up 24 Months"},{"categories":[{"measurements":[{"groupId":"OG000","value":"35.8"},{"groupId":"OG001","value":"30.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"455"},{"groupId":"OG001","value":"443"}],"units":"Participants"}],"title":"Role Functioning, Cycle 3 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"30.1"},{"groupId":"OG001","value":"33.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"438"},{"groupId":"OG001","value":"422"}],"units":"Participants"}],"title":"Role Functioning, Cycle 5 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"31.2"},{"groupId":"OG001","value":"30.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"413"},{"groupId":"OG001","value":"401"}],"units":"Participants"}],"title":"Role Functioning, Cycle 8 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"32.9"},{"groupId":"OG001","value":"32.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"377"},{"groupId":"OG001","value":"358"}],"units":"Participants"}],"title":"Role Functioning, Cycle 12 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"27.6"},{"groupId":"OG001","value":"33.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"333"},{"groupId":"OG001","value":"311"}],"units":"Participants"}],"title":"Role Functioning, Cycle 16 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"27.3"},{"groupId":"OG001","value":"34.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"253"},{"groupId":"OG001","value":"233"}],"units":"Participants"}],"title":"Role Functioning, Cycle 20 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"28.6"},{"groupId":"OG001","value":"28.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"370"},{"groupId":"OG001","value":"367"}],"units":"Participants"}],"title":"Role Functioning, Completion of Treatment/ Early Termination Visit"},{"categories":[{"measurements":[{"groupId":"OG000","value":"25.1"},{"groupId":"OG001","value":"27.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"235"},{"groupId":"OG001","value":"236"}],"units":"Participants"}],"title":"Role Functioning, Post-Treatment Follow Up 3 Months"},{"categories":[{"measurements":[{"groupId":"OG000","value":"24.5"},{"groupId":"OG001","value":"29.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"147"},{"groupId":"OG001","value":"164"}],"units":"Participants"}],"title":"Role Functioning, Post-Treatment Follow Up 6 Months"},{"categories":[{"measurements":[{"groupId":"OG000","value":"23.8"},{"groupId":"OG001","value":"34.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"84"},{"groupId":"OG001","value":"98"}],"units":"Participants"}],"title":"Role Functioning, Post-Treatment Follow Up 9 Months"},{"categories":[{"measurements":[{"groupId":"OG000","value":"33.3"},{"groupId":"OG001","value":"34.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"45"},{"groupId":"OG001","value":"58"}],"units":"Participants"}],"title":"Role Functioning, Post-Treatment Follow Up 12 Months"},{"categories":[{"measurements":[{"groupId":"OG000","value":"42.9"},{"groupId":"OG001","value":"25.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"16"}],"units":"Participants"}],"title":"Role Functioning, Post-Treatment Follow Up 18 Months"},{"categories":[{"measurements":[{"groupId":"OG000","value":"50"},{"groupId":"OG001","value":"66.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"6"}],"units":"Participants"}],"title":"Role Functioning, Post-Treatment Follow Up 24 Months"},{"categories":[{"measurements":[{"groupId":"OG000","value":"40.7"},{"groupId":"OG001","value":"36.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"455"},{"groupId":"OG001","value":"442"}],"units":"Participants"}],"title":"Social Functioning, Cycle 3 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"37.6"},{"groupId":"OG001","value":"36.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"439"},{"groupId":"OG001","value":"422"}],"units":"Participants"}],"title":"Social Functioning, Cycle 5 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"40.2"},{"groupId":"OG001","value":"35.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"413"},{"groupId":"OG001","value":"403"}],"units":"Participants"}],"title":"Social Functioning, Cycle 8 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"38.3"},{"groupId":"OG001","value":"39.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"376"},{"groupId":"OG001","value":"357"}],"units":"Participants"}],"title":"Social Functioning, Cycle 12 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"36.6"},{"groupId":"OG001","value":"33.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"333"},{"groupId":"OG001","value":"312"}],"units":"Participants"}],"title":"Social Functioning, Cycle 16 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"34.1"},{"groupId":"OG001","value":"33.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"252"},{"groupId":"OG001","value":"234"}],"units":"Participants"}],"title":"Social Functioning, Cycle 20 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"31.9"},{"groupId":"OG001","value":"31.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"367"},{"groupId":"OG001","value":"367"}],"units":"Participants"}],"title":"Social Functioning, Completion of Treatment/ Early Termination Visit"},{"categories":[{"measurements":[{"groupId":"OG000","value":"30.3"},{"groupId":"OG001","value":"32.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"234"},{"groupId":"OG001","value":"236"}],"units":"Participants"}],"title":"Social Functioning, Post-Treatment Follow Up 3 Months"},{"categories":[{"measurements":[{"groupId":"OG000","value":"33.8"},{"groupId":"OG001","value":"34.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"148"},{"groupId":"OG001","value":"164"}],"units":"Participants"}],"title":"Social Functioning, Post-Treatment Follow Up 6 Months"},{"categories":[{"measurements":[{"groupId":"OG000","value":"27.4"},{"groupId":"OG001","value":"30.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"84"},{"groupId":"OG001","value":"98"}],"units":"Participants"}],"title":"Social Functioning, Post-Treatment Follow Up 9 Months"},{"categories":[{"measurements":[{"groupId":"OG000","value":"28.9"},{"groupId":"OG001","value":"25.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"45"},{"groupId":"OG001","value":"58"}],"units":"Participants"}],"title":"Social Functioning, Post-Treatment Follow Up 12 Months"},{"categories":[{"measurements":[{"groupId":"OG000","value":"28.6"},{"groupId":"OG001","value":"18.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"16"}],"units":"Participants"}],"title":"Social Functioning, Post-Treatment Follow Up 18 Months"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"16.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"6"}],"units":"Participants"}],"title":"Social Functioning, Post-Treatment Follow Up 24 Months"},{"categories":[{"measurements":[{"groupId":"OG000","value":"57.5"},{"groupId":"OG001","value":"57.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"454"},{"groupId":"OG001","value":"443"}],"units":"Participants"}],"title":"Emotional Functioning, Cycle 3 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"52.4"},{"groupId":"OG001","value":"53.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"439"},{"groupId":"OG001","value":"422"}],"units":"Participants"}],"title":"Emotional Functioning, Cycle 5 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"53.2"},{"groupId":"OG001","value":"54.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"412"},{"groupId":"OG001","value":"403"}],"units":"Participants"}],"title":"Emotional Functioning, Cycle 8 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"53.2"},{"groupId":"OG001","value":"50.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"376"},{"groupId":"OG001","value":"357"}],"units":"Participants"}],"title":"Emotional Functioning, Cycle 12 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"55.0"},{"groupId":"OG001","value":"51.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"333"},{"groupId":"OG001","value":"312"}],"units":"Participants"}],"title":"Emotional Functioning, Cycle 16 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"49.2"},{"groupId":"OG001","value":"52.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"252"},{"groupId":"OG001","value":"234"}],"units":"Participants"}],"title":"Emotional Functioning, Cycle 20 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"53.0"},{"groupId":"OG001","value":"51.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"368"},{"groupId":"OG001","value":"367"}],"units":"Participants"}],"title":"Emotional Functioning, Completion of Treatment/ Early Termination Visit"},{"categories":[{"measurements":[{"groupId":"OG000","value":"51.3"},{"groupId":"OG001","value":"55.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"234"},{"groupId":"OG001","value":"236"}],"units":"Participants"}],"title":"Emotional Functioning, Post-Treatment Follow Up 3 Months"},{"categories":[{"measurements":[{"groupId":"OG000","value":"48.6"},{"groupId":"OG001","value":"47.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"148"},{"groupId":"OG001","value":"164"}],"units":"Participants"}],"title":"Emotional Functioning, Post-Treatment Follow Up 6 Months"},{"categories":[{"measurements":[{"groupId":"OG000","value":"53.6"},{"groupId":"OG001","value":"48.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"84"},{"groupId":"OG001","value":"98"}],"units":"Participants"}],"title":"Emotional Functioning, Post-Treatment Follow Up 9 Months"},{"categories":[{"measurements":[{"groupId":"OG000","value":"46.7"},{"groupId":"OG001","value":"43.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"45"},{"groupId":"OG001","value":"58"}],"units":"Participants"}],"title":"Emotional Functioning, Post-Treatment Follow Up 12 Months"},{"categories":[{"measurements":[{"groupId":"OG000","value":"50.0"},{"groupId":"OG001","value":"37.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"16"}],"units":"Participants"}],"title":"Emotional Functioning, Post-Treatment Follow Up 18 Months"},{"categories":[{"measurements":[{"groupId":"OG000","value":"50.0"},{"groupId":"OG001","value":"16.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"6"}],"units":"Participants"}],"title":"Emotional Functioning, Post-Treatment Follow Up 24 Months"},{"categories":[{"measurements":[{"groupId":"OG000","value":"43.3"},{"groupId":"OG001","value":"42.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"455"},{"groupId":"OG001","value":"443"}],"units":"Participants"}],"title":"GHS/OoL, Cycle 3 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"42.6"},{"groupId":"OG001","value":"44.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"439"},{"groupId":"OG001","value":"422"}],"units":"Participants"}],"title":"GHS/OoL, Cycle 5 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"39.0"},{"groupId":"OG001","value":"42.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"413"},{"groupId":"OG001","value":"403"}],"units":"Participants"}],"title":"GHS/OoL, Cycle 8 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"40.7"},{"groupId":"OG001","value":"42.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"376"},{"groupId":"OG001","value":"357"}],"units":"Participants"}],"title":"GHS/OoL, Cycle 12 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"38.4"},{"groupId":"OG001","value":"43.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"333"},{"groupId":"OG001","value":"312"}],"units":"Participants"}],"title":"GHS/OoL, Cycle 16 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"36.9"},{"groupId":"OG001","value":"42.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"252"},{"groupId":"OG001","value":"234"}],"units":"Participants"}],"title":"GHS/OoL, Cycle 20 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"37.2"},{"groupId":"OG001","value":"40.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"368"},{"groupId":"OG001","value":"367"}],"units":"Participants"}],"title":"GHS/OoL, Completion of Treatment/ Early Termination Visit"},{"categories":[{"measurements":[{"groupId":"OG000","value":"38.9"},{"groupId":"OG001","value":"38.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"234"},{"groupId":"OG001","value":"236"}],"units":"Participants"}],"title":"GHS/OoL, Post-Treatment Follow Up 3 Months"},{"categories":[{"measurements":[{"groupId":"OG000","value":"39.9"},{"groupId":"OG001","value":"42.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"148"},{"groupId":"OG001","value":"164"}],"units":"Participants"}],"title":"GHS/OoL, Post-Treatment Follow Up 6 Months"},{"categories":[{"measurements":[{"groupId":"OG000","value":"39.3"},{"groupId":"OG001","value":"38.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"84"},{"groupId":"OG001","value":"98"}],"units":"Participants"}],"title":"GHS/OoL, Post-Treatment Follow Up 9 Months"},{"categories":[{"measurements":[{"groupId":"OG000","value":"42.2"},{"groupId":"OG001","value":"32.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"45"},{"groupId":"OG001","value":"58"}],"units":"Participants"}],"title":"GHS/OoL, Post-Treatment Follow Up 12 Months"},{"categories":[{"measurements":[{"groupId":"OG000","value":"35.7"},{"groupId":"OG001","value":"37.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"16"}],"units":"Participants"}],"title":"GHS/OoL, Post-Treatment Follow Up 18 Months"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"16.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"6"}],"units":"Participants"}],"title":"GHS/OoL, Post-Treatment Follow Up 24 Months"}],"denoms":[{"counts":[{"groupId":"OG000","value":"473"},{"groupId":"OG001","value":"473"}],"units":"Participants"}],"description":"Percentage of participants who remain stable defined as changes within 10 points from the baseline score on each of the functional (physical, role, emotional, and social) and GHS/QoL scales of the EORTC QLQ-C30.","groups":[{"description":"Participants in the primary tumor-reductive surgery group received paclitaxel, carboplatin, atezolizumab placebo IV infusion on Day 1 of each 21-day cycle for a total of 6 cycles, and bevacizumab IV infusion starting with Cycle 2 for a total of 5 cycles, followed by maintenance therapy bevacizumab with atezolizumab placebo for a total of 22 cycles of atezolizumab placebo and 21 cycles of bevacizumab. Participants in the neoadjuvant therapy group received paclitaxel, carboplatin and placebo for 6 cycles and bevacizumab for 4 cycles. Interval surgery will occur between cycles 3 and 4. Each cycle is 21 days long. After 6 cycles, participants started maintenance therapy of bevacizumab and placebo for additional 16 cycles.","id":"OG000","title":"Placebo With Paclitaxel, Carboplatin and Bevacizumab"},{"description":"Participants in the primary tumor-reductive surgery group received paclitaxel, carboplatin, atezolizumab intravenous (IV) infusion on Day 1 of each 21-day cycle for a total of 6 cycles, and bevacizumab IV infusion starting with Cycle 2 for a total of 5 cycles, followed by maintenance therapy bevacizumab with atezolizumab for a total of 22 cycles of atezolizumab and 21 cycles of bevacizumab. Participants in the neoadjuvant therapy group received paclitaxel, carboplatin and atezolizumab for 6 cycles and bevacizumab for 4 cycles. Interval surgery will occur between cycles 3 and 4. Each cycle is 21 days long. After 6 cycles, participants started maintenance therapy of bevacizumab and atezolizumab for additional 16 cycles.","id":"OG001","title":"Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab"}],"paramType":"NUMBER","populationDescription":"PRO-evaluable population is defined as patients in the ITT population with a baseline and \\>=1 post-baseline PRO assessment.","reportingStatus":"POSTED","timeFrame":"From randomization to the end of treatment/discontinuation (up to approximately 66 weeks), and during follow-up period (up to approximately 55 months). Cycle length=21 days.","title":"Percentage of Participants Who Remain Stable in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}